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Introduction
Hemophilia B is an X-linked disorder caused by the deficiency of factor IX (FIX) activity. The clinical severity of the disease is inversely proportional to FIX levels in the plasma. Severe hemophilia B patients maintain Ͻ1% of normal FIX levels and develop frequent spontaneous bleeding episodes. Patients with FIX levels ranging from 1 to 5% are phenotypically moderate, whereas spontaneous bleeding rarely occurs in patients with FIX plasma levels Ͼ5%. Current therapy is based on intravenous infusion of FIX concentrates, either viral-inactivated plasma-derived or recombinant protein. 1, 2 In general, these FIX products are effective and considered safe. Concerns about possible transmissible agents persist, however, highlighted by recent hepatitis A transmissions 3 and product recalls due to Creutzfeld-Jacob disease in plasma donors. 4 Bolus infusion with FIX concentrate provides circulating FIX with a half-life of 18-30 h. Effective prophylactic treatment can be achieved by twice-a-week infusions when trough levels are at least Ͼ1% FIX. 5 Such prophylactic regimens are the standard of care for hemophilic children in Sweden and several European countries. 5, 6 However, due to higher factor requirement, the cost of prophylactic treatment is prohibitive for most adult patients.
Gene therapy is an attractive approach capable of affecting sustained therapeutic levels of circulating FIX for a long duration. Although several different viral vectors have been used for the delivery of the FIX gene, vectors to date suffer from either low transduction 7 or exuberant immune response to the vector. 8 Recombinant adeno-associated virus (rAAV) has several features which are suited for FIX gene expression. rAAV is nonpathogenic and has a broad cell range of infection. 9 The vector capsid is comprised of primarily one major polypeptide (Vp3) 10 and does not elicit a cell-mediated immunologic response. [11] [12] [13] The packaging restriction of the 4.6 kb AAV genome 14, 15 limits the use of large cDNAs. Fortunately, this is not a problem for FIX cDNA (1.4 
kb).
Skeletal muscle is an excellent target tissue for rAAV vectors. A rAAV vector carrying the beta-galactosidase (␤-gal) transgene expressed ␤-gal for over 1.5 years in vivo following direct intramuscular injection in young immunocompetent mice. 13, 16 The immune response was limited to the development of anti-AAV neutralizing antibodies. No cellular response was mounted against the rAAV-transduced cells. 13, 16 Skeletal muscle is capable of performing the necessary post-translational modifications required for functional FIX protein. 17 rAAV-2 targeting of skeletal muscle produces human FIX circulating levels up to 7% of normal human levels in immunodeficient mice. neutralizing (inhibitor) antibodies to the human FIX precluded any evaluation of FIX function. 21 Here, we report on the expression and functional assessment of AAVmediated canine FIX (cFIX) following intramuscular injection in two hemophilia B canines.
Results
In vitro cFIX expression Two rAAV vectors expressing cFIX ( Figure 1 ) were tested for FIX expression. cFIX cDNA was driven by a CMV promoter (rAAV/cFIX). The constructs differed only with the inclusion of a truncated human intron 1 (rAAV/cFIX.In). The intronic sequence is argued to promote FIX expression by stabilizing mRNA. 22 1.2 × 10 13 particles of rAAV/cFIX.In and 6 × 10 12 particles of rAAV/cFIX were produced by transient cotransfection of 293 cells. 23 This transfection scheme produced no detectable adenovirus (data not shown). 23 Cell lysates were harvested at 48 h and rAAV concentrated by salt precipitation and density gradient centrifugation. rAAV genome number was determined by dot blot hybridization where less than 0.1% of wild-type (wt) AAV genomes were detected (data not shown). Functional wt AAV particles were estimated at Ͻ1 infectious particle/10 7 particles by infectious center assay (data not shown).
To test for cFIX expression, 293, HeLa or primary fibroblast cells were transduced as follows. rAAV/cFIX or rAAV/cFIX.In were added at 1 × 10 5 particles per cell. Every 24 h the cell medium was removed and analyzed for cFIX protein by ELISA and Western blotting. cFIX protein expression in all three cell types tested yielded similar results. cFIX protein expression peaked at 150-180 ng/ml from 2 × 10 5 293 cells/24 h (Figure 2a ). The activated partial thromboplastin time (APTT) was used to determine if the secreted cFIX was functional. cFIX levels were equivalent to 6-7% of normal dog plasma (data 24 Transduced 293 cells were also analyzed for rAAV/cFIX mRNA. Quantification of vector-specific mRNA revealed a 10-fold greater rAAV/cFIX.In mRNA level compared with the intron-less vector (Figure 2b) . These results are consistent with in vitro evidence of enhanced FIX transcription with human FIX intron I. 22 Despite the greater abundance of cFIX rAAV/cFIX.In mRNA, the secreted cFIX protein levels were equivalent suggesting post-transcriptional rate-limiting events.
rAAV/cFIX expression in hemophilia B canines Hemophilia B canines were selected for our study after screening serum for neutralizing anti-AAV2 plasma antibodies. Since the dogs routinely receive canine parvovirus vaccinations, this analysis was performed to ensure that no pre-existing or cross-reacting antibody to AAV2 would interfere with our experiments. Canine parvovirus is an autonomous parvovirus which is related to AAV, a member of the dependent parvovirus genus. 25 Serum from five animals was incubated with a test rAAV virion carrying the ␤-gal gene. The virions were applied to HeLa cells and assayed for infectivity as previously reported. 26 No inhibitory activity was detected in serum from these untreated dogs (data not shown).
Intramuscular AAV transduction appears to be more efficient in young animals. 13 rAAV/cFIX.In/kg) (see Table 1 ). The total vector dose was divided equally and injected into 10 separate skeletal muscle sites. No acute local or systemic inflammatory response was observed following the injection. As expected, we observed an increase in the serum creatine phosphokinase (CPK) levels reaching a maximum of 1.5 times baseline; plasma CPK levels, which reflect myocyte damage, returned to baseline within 1 week (data not shown).
To assess the hemostatic status of the animals, whole blood clotting time (WBCT) was performed. The preinjection WBCT for B83 and B86 were Ͼ60 min and 48 min, respectively. The range for WBCT in non-hemophilic littermates is 8-10 min. The WBCT for each experimental animal steadily decreased over a period of 6-to-7 weeks. The WBCT remained at a steady level of 15 to 20 min which persisted until B86 was killed at 9 months Figure 3 ). B83 now 18 months after injection, maintains a WBCT of 16-18 min. The plasma cFIX antigen level increased over a 6-7 week period reaching a stable level of 120-140 ng/ml for both canines (see Figure 3 ). This gradual trend in AAV-mediated muscle expression is a common finding, not dependent on the type of protein expressed or the animal model.
21,27
Despite the difference in vector dose no significant difference in cFIX antigen was observed between the two animals. The APTT confirmed that canine FIX was functional (see Table 2 ). Although WBCT was shortened and 1-2% of cFIX was detected in the circulation, both animals still experienced spontaneous and traumatic bleeding episodes that required plasma transfusions ( Figure 3 ) (see Table 2 ). Transfusions shorten the APTT and WBCT. For this reason we sampled the dogs several days to weeks after transfusions to avoid artefactual reduction of the hemostatic parameters.
Tissue analysis
Due to severe hip dysplasia B86 was killed at week 33 after vector administration and tissues were collected for molecular, immunological and pathologic analysis. Immunohistochemical staining of skeletal muscle tissue detected cFIX expression in muscle fibrils located at the site of vector injection but not at the injection tract where PBS and the carbon particle solution were administered (see Figure 4c , f). Carbon particles were used to locate the injection sites at the time the animal was killed.
To test for anti-rAAV-2 capsid antibodies, rAAV/␤-gal virus was incubated with dilutions of canine serum. Virions were subsequently used to transduce HeLa cells. Neutralizing antibodies to AAV2 inhibited transduction, as measured by the lack of blue staining cells (see Figure 5 ). We could detect inhibition of rAAV/␤-gal transduction as early as 1 week after vector administration. A 1:100 dilution of canine serum was required to observe 100% blue cells. This inhibitory dilution remained unchanged over the experimental period for both dogs (data not shown). Using a modified Bethesda assay, we did not detect FIX inhibitors at any time after administration of rAAV vectors in either animal (data not shown).
The histologic analysis revealed a few small foci of lymphocytes surrounding muscle fibers (see Figure 4d , e). Pathologic changes in the muscle fibers were reflected by central displacement of the nuclei. No infiltration of lymphocytes was seen in stained sections taken from the control injection site. The inflammatory response is quite modest compared with the large areas of damaged tissue when adenoviral containing preparations are used. 21 At present, we do not have a biological reason for this response.
Molecular analysis of rAAV
Tissue expression: Previous experience suggested that rAAV/hFIX genomes were restricted to skeletal muscle and draining lymphatics. 21 Using DNA PCR, a primer pair was designed to amplify a 400 bp fragment unique to rAAV/cFIX.In. Genomic DNA isolated from liver, spleen, kidney, lymph node, brain, intestine, spinal cord, ovaries and peripheral blood mononuclear cells were tested. Only genomic DNA isolated from tissue at the injection sites produced the appropriate size PCR product (Figure 6a ). To confirm that the skeletal muscle was the source of cFIX expressed, RT-PCR was performed. We detected the appropriate PCR fragment from liver and the vectorinjected muscle tissue only (Figure 6b ). Primer pairs to ␤-actin were used as an internal control for RT-PCR. These results confirmed skeletal muscle as the source of circulating functional cFIX.
Figure 3 Hemostatic analysis of dogs B83 and B86. Whole blood clotting time (WBCT) was performed at weekly intervals following rAAV administration. The baseline WBCT were Ͼ40 min for each dog. (a) and (b) WBCT activity for B83 and B86, respectively; normal WBCT (represented by shaded horizontal bar) is 8-10 min. (c) and (d) Plasma cFIX levels for B83 and B86, respectively. Arrows indicate plasma infusion required to treat a bleeding event.

Molecular fate of the rAAV genome:
The long-term persistent expression of circulating cFIX in vivo suggested that rAAV stably transduced skeletal muscle cells. To determine more precisely the molecular state of the rAAV genome, we isolated both high and low molecular weight DNA pooled from skeletal muscle at 9 months following injection. High molecular weight genomic DNA was digested with restriction enzyme BglII, which cuts within each ITR. The digested DNA was hybridized with a vector-specific 5′ probe (CMV promoter). As shown in Figure 7 , when the BglII-digested high molecular weight DNA was hybridized 5′ probe, a 4.0 kb rAAV genome band was identified at the level of five to 10 genome copies per cell. Further analysis of HMW DNA suggests that the multiple vector copies are arranged as head-to-tail concatemers (data not shown). Analysis of low molecular weight (Hirt) DNA from injection site muscle tissue results clearly demonstrates the presence of (4.0 kb) the rAAV genome at the level of five to 10 vector genome copies per cell (see Figure 7 ).
Discussion
We report the long-term expression of cFIX in two hemophilia B canines. rAAV introduced intramuscularly produced sustained circulating levels at 1-2% of normal canine FIX levels. Partial correction of hemostasis was demonstrated. The persistent expression of cFIX is explained by stably transduced muscle cells. The rAAV genome existed as both high molecular weight and episomal forms. No toxicity was associated with the intramuscular use of rAAV and the immune response was limited to the development of neutralizing antibodies to the AAV-2 capsid. No antibody (inhibitor) to cFIX was detected.
Long-term prophylactic doses of FIX given to children with severe disease has a tremendous impact on outcome. Prophylactic regimens significantly reduce arthropathy and soft tissue bleeding in patients with severe hemophilia who are begun on prophylaxis at 1 to 2 years of age and whose trough levels of FIX are maintained above 1%. 1, 5, 6, 28 In contrast to patient studies, we found that despite plasma cFIX levels of 1-2%, bleeding still occurred in both dogs. The majority of the bleeding episodes were trauma-related but spontaneous bleeding did occur. Given that prophylactic doses of factor have a predictable fall off with trough levels lasting a few hours, this suggests that higher sustained FIX levels are needed. Indeed the children receiving twice-a-week FIX prophylaxis were maintained at pre-infusion levels ranging from 1 to 9% (mean levels 3-4%). Other groups using rAAVmediated cFIX gene transfer in the Chapel Hill dogs reported similar plasma levels of cFIX to ours, with transfusion required for bleeding. 29, 30 Taken together, these reports indicate that higher trough levels may be required before any significant clinical efficacy occurs.
We constructed two rAAV vectors to test whether alterations in the cFIX mRNA level would lead to improved FIX expression. The incorporation of intronic elements, which reduce FIX mRNA degradation, improve FIX expression. 22 In vitro testing of rAAV/cFIX.In confirmed that the inclusion of the intronic sequence provided mRNA stability. However, no increase in cFIX levels was obtained in vivo. This result suggests that ratelimiting steps which may be post-transcriptional in skeletal muscle are responsible for active FIX. It remains for further study to determine if translational, secretory or extracellular processes limit FIX plasma levels.
When 10 11-12 rAAV vectors were injected into skeletal muscle mice weighing 25 g, up to 7% of normal human FIX levels were detected in the plasma.
18,31 10 12-13 rAAV particles administered to 5-10 kg canines produced 1-2% of normal FIX levels. Assuming equipotency of vector in human muscle, we estimate that 10 14-15 vector particles will be required for an average 70 kg adult patient. This highlights a significant technical limitation and suggests that vector production, purification and administration strategies need to be improved. The current method for generating rAAV, cotransfection into producer cells, is not feasible for large-scale production required for clinical use. Current packaging cell lines are still inadequate. 9 The recent identification of heparan sulfate, 32 integrin ␣ v ␤ 5 33 and fibroblast growth factor receptor 34 as AAV coreceptors provides for the rapid purification of vector 
Viral transduction was measured by the number of blue-staining cells using pre-injection (a) and after injection (day 98) B83 serum (b). Similar results were obtained using B86 sera.
using column chromatography. 35 Per particle, column purified virus is more infectious than cesium-banded material. Virus purification using this procedure should reduce the risk of immune response given the high dose of vector required for patients.
Elimination of adenovirus in the vector preparation dramatically reduces the immune response. 21 However, a few small foci of lymphocytes were still detected at the injection site. Using Bethesda assay, we did not find FIX inhibitor at anytime after injections of rAAV vectors (data not shown). 2, 29, 30 However, the antibodies that developed against AAV2 were detected in the plasma of both dogs as early as 1 week after injections. These results are consistent with previous reports of neutralizing antibody in mice. 13 Studies are ongoing to determine if AAV-2 vector re-administration is feasible. Re-administration may be possible by the use of other AAV serotype vectors which are not cross-reactive. 36 The lag phase of transgenic protein expression of 6 to 7 weeks has been observed with the rAAV-mediated gene expression. 27, 29, 30, 37, 38 One explanation for this phenomenon is the conversion of single-stranded rAAV genomes to transcriptionally active duplex-stranded templates (whether integrated or episomal). 26, 39 The conversion of monomer to high molecular weight forms has been described. 13, 30 The mechanism for this conversion may proceed through circular intermediates. [40] [41] [42] Whether AAV circular intermediates are also a prerequisite for chromosomal integration is unclear. Unlike previous studies, we found a persistence of several molecular forms (single-strand, replicative intermediate, monomer, dimer and high molecular weight). It is not clear if all, or some of the molecular species are capable of FIX expression. Further analysis and determination of the relative contribution of each AAV species is ongoing.
The gradual appearance of cFIX in the plasma may also reflect its binding to vascular endothelial binding sites and its distribution between intravascular and extravascular compartments.
2 FIX binding to endothelial collagen type IV 43 has been documented and explains in part the infusion requirement for larger doses of FIX than FVIII. 44 The binding equilibrium between FIX and available collagen binding sites in the interstitium may certainly play a role in maintaining plasma protein levels.
rAAV direct intramuscular injection is a crude method and capable of transducing a variety of cell types. Differences in the transduction of myocytes, myoblasts, satellite cells and interstitial cells may contribute to the gradual onset of circulating cFIX levels. The 'checkerboard' staining appearance we observe for cFIX may represent transduction and expression of different muscle cell types.
Although the results are encouraging, we could not demonstrate a definitive phenotypic improvement. The animals still suffered from both spontaneous and traumatic bleeding episodes which necessitated plasma transfusions. This is consistent with the low 1-2% levels of cFIX reported here and recently by others. 29, 30 A recent report employing intravenous rAAV injection at the time of histamine-induced endothelial permeability demonstrated the transduction of the distal hindlimb musculature. 45 These results strongly imply that improvements in vector delivery and protein expression are achievable. Therefore, safe and efficient transduction seems achievable for AAV-mediated hemophilia B gene therapy.
Materials and methods
Cells and culture 293, HeLa and primary fibroblasts from the hemophilia B canine were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco/BRL, Gaithersburg, MD, USA) with 10% fetal bovine serum (FBS, Gibco/BRL), with or without antibiotics (penicillin and streptomycin), at 37°C incubator with 5% CO 2 . FBS was depleted of factor IX by barium sulfate precipitation. FBS-depleted FIX was tested by ELISA and APTT assay and neither FIX antigen nor activity were detected.
Animal care
The hemophilia B canines were maintained at the Francis Owen Blood Laboratory at the University of North Carolina at Chapel Hill in accordance with the guidelines of the UNC Institutional Animal Care and Use Committee. The canines used in this study were free of antibodies capable of inhibiting rAAV2 transduction. Each animal was sedated using sodium thiopental (Abbott Laboratory) before virus administration. Each animal received intramuscular injection of virus at 10 different sites. Each injection consisted of 0.5 ml of vector in phosphate-buffered saline (PBS) and 0.5 l of carbon particle solution. Individual muscles in all four limbs were injected. The animals tolerated the procedure without evidence of local or systemic allergic response. Occasional subcutaneous bleeding occurred at the time of injection. Blood was collected weekly for functional and immunologic testing. The whole blood clotting time (WBCT), one-step activated partial prothrombin time (APTT), cFIX ELISA, anti-cFIX antibodies and anti-AAV antibodies were assayed. Canine B86 was killed on day 242 (week 33) after administration of rAAV. Tissues/organs were collected for histology and DNA/RNA analyses. Tissues collected included muscle from a mock injection site (carbon particles +PBS), rAAV injection sites, draining lymph nodes, liver, spleen, kidney, ovaries, heart, brain, spinal cord and intestine. Tissues were either snap frozen at −80°C or fixed in 10% neutral-buffered formalin overnight before processing.
Vector constructs
Two rAAV plasmids were constructed. Briefly, the plasmid LNCdF9L (gift from Dr I Verma, Salk Institute) was used as the template to amplify the 1.5 kb of the cDNA sequence of canine FIX (cFIX), and the plasmid pBS/Me4bAIXml (gift from Dr K Kurachi, University of Michigan) as the template of the 1.4 kb truncated intron I of the human FIX. The cFIX cDNA was subcloned into plasmid pTR-UF5 (gift from Dr N Muzyczka, University of Florida), flanked by the AAV inverted terminal repeat sequences (ITRs), designated pAAV/cFIX. The intron I sequence was ligated to the 3′ end of the cFIX coding sequence of pAAV/cFIX to generate plasmid pAAV/cFIXIn. Both constructs employ the cytomegalovirus (CMV) early-immediate promoter and the bovine growth hormone polyadenylation signal. All DNA sequences amplified by PCR were verified by sequencing.
rAAV production and purification rAAV was produced using a three plasmid transfection scheme previously described. 23, 46 Briefly, subconfluent 293 cells were cotransfected with the rAAV vector plasmid (pAAV/cFIX or pAAV/cFIX.In), AAV helper plasmid pACG and adenovirus helper plasmid XX6 using calcium phosphate precipitation. Forty-eight hours after transfection, the cells were harvested, lysed by three cycles of freeze-thawing and sonicated to release the rAAV. Following ammonium sulfate precipitation, the virus particles were concentrated twice by cesium chloride density gradient centrifugation. Viral particles were titered by dot-blot, the rAAV/cFIX peak gradient fractions pooled, dialyzed against phosphate buffer saline (PBS), and stored at −20°C.
In vitro expression of canine FIX 2 × 10 5 293 Cells, HeLa cells or hemophilic canine primary fibroblasts were plated in each well of six-well plates. Twelve to 20 h after plating, cells were transduced with 1 × 10 5 rAAV virus particles per cell, with or without adenovirus (MOI = 1) for 1 h. The cell medium was harvested for analysis and replaced with fresh medium every 24 h after infection. All the medium/serum used for assaying cFIX expression and function was depleted of FIX.
Antigen assay for canine FIX Canine FIX antigen was detected by enzyme-linked immunosorbent assay (ELISA). Briefly, the flat-bottom high-binding 96-well plates (Costar) were coated with 1 g/ml of monoclonal mouse anti-human FIX antibody (Boerhinger Mannheim) in 0.1 m carbonate buffer (pH у 9.5) at 4°C overnight. The wells were washed three times with the washing buffer (PBS with 0.25% Tween 20) and blocked with the diluting buffer (the washing buffer with 1% (v/w) bovine serum albumin) at 37°C for 1 h. Following three washes with the washing buffer, the well was loaded with the samples, and incubated at 37°C for 1 h. The plate was rinsed three times with the washing buffer, loaded with the peroxidase-conjugated sheep anti-FIX antibody (Affinity Chemical, Canada) and incubated at 37°C for 1 h. The plates were washed, 100 l of ABTS solution added (Boerhinger Mannheim), and absorbency read at 405 nm with a microplate reader (Bio-TEK Instruments, Winooski, VT, USA). The FIX levels were calculated according to the standard curve derived from serial dilution of the pooled normal dog plasma. The sensitivity of the ELISA for canine FIX was determined to be 2.0 ng/ml.
Activity assay for canine FIX
The procoagulation activity of the recombinant cFIX was tested by the activated partial thromboplastin time (APTT) using the fibrometer method. Briefly, 75 l of FIX-deficient plasma (Pacific Hemostasis), silicate particles (Pacific Hemostasis) and the serum or cell medium were mixed and incubated at 37°C for exactly 3 min. Upon the addition of 75 l of pre-warmed (37°C) 20 mm CaCl 2 , the fibrometer recorded the clot forming time of each sample. Each sample was performed in duplicate and the average taken as the clotting time. A serial dilution of pooled normal dog plasma was used to generate the standard curve.
DNA isolation and Southern blot analysis
Tissue samples were frozen in liquid nitrogen and then pulverized using a mortar and pestle. Low molecular weight DNA (viral DNA) was isolated according to the method of Hirt. 47 High molecular weight DNA was isolated from the residual material. 48 The high molecular weight DNA was digested with restriction enzyme BglII, and separated using non-denaturing or alkaline agarose gels. DNA were transferred to nylon membrane (Hybond-N+; Amersham), and hybridized with ␣-32 P-labeled probes. A BspEI and BglII digest of pAAV/FIXIn yielded a 600 bp CMV promoter probe.
RNA extraction and Northern blot
Total cellular RNA was extracted using Purescript RNA isolation kit (Gentra System), following the manufacturer's protocol. 10 g of RNA was electrophoresed using a 1.0% formaldehyde gel, 49 transferred on to nylon membrane (Hybond-N+; Amersham), and hybridized with ␣-32 P-labeled cFIX probe (1.4 kb), BspEI and NotI digest of pAAV/cFIX).
Reverse transcription (RT)-PCR and DNA PCR of tissues
The total cellular RNA and genomic DNA from animal B86 was isolated from portions of skeletal muscle, brain, spinal cord, liver, spleen, lymph nodes, kidney, lungs, heart and ovaries. Reverse transcription of 5 g RNA was performed using Supertranscript II RT (Gibco/BRL) at 42°C for 50 min. 200 ng of genomic DNA was used for DNA PCR. Primers specific for the cFIX/In junction included the upstream primer 5′-CGGTCCAC-GAAGTTCACC-3′ and downstream primer 5′-ACCAG-TACTTACCAACCTGC-3′. The PCR conditions were 95°C for 5 min followed by 30 cycles with 95°C for 2 min, 50°C for 1 min, 72°C for 1 min. The primers used for RT/PCR of the cFIX transcript included an upstream primer 5′-AGAGTTTGTTCGAGGGAACC-3′ and the downstream primer 5′-AATGGTGAACTTCGTGGACC-3′ using the amplification conditions 95°C for 2 min, followed with 30 cycles of 95°C for 1 min, 55°C for 1 min, 72°C for 1 min. A pair of ␤-actin primers was used for each sample as an internal control.
Western blot analysis
Briefly, rAAV/transduced 293 cells were harvested and stored at −80°C. The samples were lysed in 50 l of lysis buffer (50 mm Tris·Cl, pH 8.0, 150 mm NaCl, 0.02% NaN 3 , 4 mm AEBSF, 1 g/ml of aprotinin, 1% Triton X-100) and the cell debris sedimented by centrifugation. 10 l of the cell lysate supernatant was loaded on to a 10% glycinetris (pH 8.3) polyacrylamide gel (Novex). Following transfer to a nitrocellulose membrane (Schleicher & Schuell), immunostaining was performed first using a rabbit anti-human FIX antibody (DAKO) incubation and a second horse radish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Kirkegaard & Perry Laboratories). The blots were then developed with chemiluminescent substrates of HRP (Supersignal substrates; Pierce) and exposed to radiographic film.
Anti-AAV antibody screen
The sera from several dogs were screened for rAAV neutralizing antibodies. Briefly, 2 × 10 5 HeLa cells were plated per well of 12-well plate. rAAV/␤-gal (2 × 10 8 particles) was preincubated with serial 10-fold dilutions of canine sera for 1 h at 4°C. Virus was added to each well; 24 h after infection the cells were fixed in 0.5% glutaraldehyde and stained for ␤-gal activity with 5-bromo-4-chloro-3-chloro-indolyl-␤-d-galactopyranoside (X-gal). Adenovirus type 2 (multiplicity of infection, MOI = 5) was added for optimal ␤-gal expression. 26 Blue cells were enumerated per field and five fields counted. The titer of the anti-AAV antibodies was determined by the reduction of blue staining cells compared with equivalent rAAV/␤-gal incubated with preinjection dog serum.
Anti-cFIX inhibitor assay
The modified Bethesda inhibitor assay (BIA) was used to detect cFIX inhibitors in dog plasma. Serial dilutions of B83 and B86 dog plasma were incubated with the pooled normal dog plasma at 37°C for 5 min. The FIX activity (APTT) was assayed to determine the amount of residual FIX activity. Titer of the cFIX inhibitor titer was calculated from a BIA standard curve.
Histological analysis
Formalin fixed tissues were alcohol dehydrated and paraffin-embedded. Tissues were sectioned at 6 m each, deparaffinized in xylene, rehydrated through graded ethanol, and either stained with hematoxylin and eosin (H&E) or immunohistochemistry performed as described previously, with minor modifications. 21 The monoclonal mouse anti-human FIX antibody (Boerhinger Mannheim) was applied as the first antibody and second antibody goat anti-mouse polyclonal conjugated with HRP (Boerhinger Mannheim).
